Anti-neoplastic effect of β-hydroxyisovalerylshikonin on a human choriocarcinoma cell line

Molecular Medicine Reports

Volumn 3, Issue 3, 2010, Pages 515-518

  Takai, Noriyuki ^a   Ueda, Tami ^a   Nishida, Masakazu ^a   Nasu, Kaei ^a   Narahara, Hisashi ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

Apoptosis; Cell cycle; Choriocarcinoma; EGFR

Indexed keywords

(3 HYDROXYISOVALERYL)SHIKONIN; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; LIPOCORTIN 5; PHOSPHATIDYLSERINE; SHIKONIN DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL GROWTH; CHORIOCARCINOMA; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MITOCHONDRIAL MEMBRANE POTENTIAL; PHENOTYPE;

LITHOSPERMUM;

EID: 77952391056     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr_00000290     Document Type: Article

References (17)

1. Jones WB, Cardinale C and Lewis JL Jr: Management of the high-risk gestational trophoblastic disease: the Memorial Hospital experience. Int J Gynecol Cancer 7: 27-33, 1997. (Pubitemid 27010014)
2. Berkowitz RS, Goldstein DP and Bernstein MR: Modified triple chemotherapy in the management of high-risk gestational trophoblastic tumors. Gynecol Oncol 19: 173-181, 1984.
3. Surwit EA and Hammond CB: Treatment of metastatic trophoblastic disease with poor prognosis. Obstet Gynecol 55: 565-570, 1980. (Pubitemid 10068252)
4. Chen X, Yang L, Oppenheim JJ and Howard OMZ: Cellular pharmacology studies of shikonin derivatives. Phytother Res 16: 199-209, 2002. (Pubitemid 34534943)
5. Hashimoto S, Xu M, Masuda Y, et al: β-Hydroxyisovalerylshikonin is a novel and potent inhibitor of protein tyrosine kinases. Jpn J Cancer Res 93: 944-951, 2002. (Pubitemid 35012257)
6. Hashimoto S, Xu M, Masuda Y, et al: β-Hydroxyisovalerylshikonin inhibits the cell growth of various cancer cell lines and induced apoptosis in leukemia HL60 cells through a mechanism different from those of Fas and etoposide. J Biochem 125: 17-23, 1999. (Pubitemid 29085955)
7. Masuda Y, Shima G, Aiuchi T, et al: involvement of tumor necrosis factor receptor-associated protein 1 (TRAP1) in apoptosis induced by β-hydroxyisovalerylshikonin. J Biol Chem 279: 42503-42515, 2004. (Pubitemid 39372134)
8. Xu Y, Kajimoto S, Nakajo S and Nakaya K: β-hydroxyisovalerylshikonin and cisplatin act synergistically to inhibit growth and to induce apoptosis of human lung cancer DMS114 cells via a tyrosine kinase-dependent pathway. Oncology 66: 67-75, 2004.
9. Takai N, Ueda T, Nishida M, Nasu K and Narahara H: Beta- hydroxyisovalerylshikonin has a profound anti-growth activity in human endometrial and ovarian cancer cells. Gynecol Oncol. 109: 107-114, 2008.
10. Xu Y, Nakajo S and Nakaya K: Synergistic inhibitory effects of transplatin and beta-hydroxyisovalerylshikon on carcinoma A431 cells involve epidermal growth factor receptor. Cancer Lett 188: 67-72, 2002.
11. Takai N, Desmond JC, Kumagai T, et al: Histone deacetylase inhibitors have a profound anti-growth activity in endometrial cancer cells. Clin Cancer Res 10: 1141-1149, 2004. (Pubitemid 38198916)
12. Takai N, Ueda T, Nishida M, Nasu K and Narahara H: Bufalin induces growth inhibition, cell cycle arrest and apoptosis in human endometrial and ovarian cancer cells. Int J Mol Med 21: 637-643, 2008.
13. Rimon G, Bazenet CE, Philpott KL and Rubin LL: Increased surface phosphatidylserine is an early marker of neuronal apoptosis. J Neurosci Res 48: 563-570, 1997. (Pubitemid 27276686)
14. Chen Y, Kramer DL, Diegelman P, Vujcic S and Porter CW: Apoptotic signaling in polyamine analogue-treated SK-MEL-28 human melanoma cells. Cancer Res 61: 6437-6444, 2001.
15. Masuda Y, Nishida A, Hori K, et al: β-Hydroxyisovalerylshikonin induces apoptosis in human leukemia cells by inhibiting the activity of a polo-like kinase 1 (PLK1). Oncogene 22: 1012-1023, 2003. (Pubitemid 36313145)
16. Johnson DG and Walker CL: Cyclins and cell cycle checkpoints. Annu Rev Pharmacol Toxicol 39: 295-312, 1999.
17. Sherr CJ: G1 phase progression: cyclin on cue. Cell 79: 551-555, 1994.